IRVINE, Calif., July 13, 2021 /PRNewswire/ -- AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell applications, today announced the publication of the peer-reviewed manuscript, "Retinal organoids on-a-chip: a 3D printed micro-millifluidic bioreactor for long-term retinal organoid maintenance," in the journal Lab on a Chip. In the study, researchers from AIVITA Biomedical and the University of California at Irvine designed and demonstrated a bioreactor for nearly labor-free retinal organoid maintenance. The success of the bioreactor serves as an important proof of concept for future clinical and commercial applications, and builds upon AIVITA Biomedical's prior success in generating 3D retinal organoids from human stem cells and demonstrating their ability to restore visual acuity to rodent models of human blindness.
Retinal degeneration is a leading cause of vision impairment and blindness worldwide, with limited treatment options available for advanced stages of the disease. Stem cell-derived retinal organoids for tissue replacement therapy have recently emerged as a promising potential treatment. However, controlled and predictable methods for manufacturing the retinal organoids are not yet standard in the industry. In this study, researchers designed a shear stress-free micro-millifluidic bioreactor for nearly labor-free retinal organoid maintenance. The result was the successful creation of bioreactor-cultured retinal organoids with cell types and morphology comparable to static cultured retinal organoids and exhibiting similar retinal gene expression levels. Researchers also observed comparable metabolic activity to tissue grown in static culture.
"To have validated an automated device that can reliably produce retinal organoids expands their potential therapeutic and diagnostic applications," said Gabriel Nistor, M.D., Chief Scientific Officer at AIVITA and a contributing author to the paper. "We look forward to exploring the therapeutic and drug-screening potential of these bioreactor-grown organoids."
AIVITA researchers believe the bioreactor may prove to be a more reliable and controlled method of producing retinal organoids, making it more suitable for producing 3D retina tissue for therapeutic use. The ability to consistently produce large quantities of tissue could also have useful applications in drug screening and formula optimization, facilitating streamlined testing of pharmaceuticals to treat vision loss.
This work is supported by funding from the California Institute for Regenerative Medicine (CIRM) and National Institutes of Health (NIH).
About AIVITA Biomedical
Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical, Inc. utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline. Our cancer immunotherapy targets the seed of all cancers, tumor-initiating cells, with a unique pan-antigenic approach that targets all neoantigens specific to the patient's cancer. Our patient-specific cancer treatments have shown tremendous promise in eradicating tumors, without harmful side effects, in melanoma and glioblastoma clinical studies.
This communication contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on a number of assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.